camoteskimab

A human immunoglobulin G1 (IgG1) monoclonal antibody against the pro-inflammatory cytokine interleukin-18 (IL-18), with potential anti-inflammatory and antineoplastic activities. Upon administration, camoteskimab selectively targets and binds to IL-18, thereby inhibiting IL-18-mediated signaling and inflammation mediated by this pathway. In addition, this may inhibit IL-18-mediated immunosuppression in the multiple myeloma microenvironment. IL-18 is a member of the interleukin-1 (IL-1) cytokine superfamily. Elevated IL-18 level is associated with disease progression and poor prognosis in multiple myeloma.